News &
Publications

Halda Therapeutics Announces Upcoming Presentation on RIPTAC Therapeutics™ at 2025 ASCO Annual Meeting

Chicago, IL – May 23, 2025 – Halda Therapeutics announced an upcoming presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago, Illinois. The poster presentation highlights advancements in the use of RIPTAC therapeutics in an ongoing Phase 1 clinical study in metastatic castrate resistant prostate cancer (mCRPC).

Presentation details are as follows:

Title: An oral prostate cancer RIPTAC therapeutic in phase 1 for metastatic castrate resistant prostate cancer (mCRPC)

Presentation Type and Abstract Number: Trial-in-Progress (TiP) TPS5115, Poster 311b
Presenter: Kat Kayser-Bricker, Ph.D., Chief Scientific Officer at Halda Therapeutics

Date: Monday, June 2, 2025
Session Time: 9 a.m. – 12 p.m. CDT
Category: Genitourinary Cancer—Prostate, Testicular, and Penile

In this abstract, Halda presents a first-in-human, multicenter, open label Phase 1/2 study (NCT06800313) to evaluate monotherapy safety, tolerability, and clinical activity of orally administered HLD-0915 AR-BRD4 RIPTAC™ therapeutic in patients with mCRPC.

Abstracts are now available via the official ASCO Annual Congress website here.

Halda is currently enrolling patients in the first-in-human, Phase 1/2 clinical trial (NCT06800313) to evaluate the safety and tolerability of HLD-0915 in the treatment of metastatic castration-resistant prostate cancer (mCRPC).  The Phase 1/2 open label, multi-center clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of orally administered, single-agent HLD-0915 in mCRPC patients. The study will include an initial Phase 1 dose escalation to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion of HLD-0915 as monotherapy and a Phase 2 expansion cohort to further evaluate the efficacy and safety of HLD-0915.

About HLD-0915

HLD-0915 is an innovative bifunctional small molecule therapy designed to selectively target prostate cancer tumors cells by holding together, with defined orientation and purpose, androgen receptor (a tumor-specific intracellular targeting protein) and a protein with essential function (effector protein). The ternary complex drives the formation of new, or neomorphic, protein-protein interactions, abrogating an essential function within cancer cells which results in an antitumor effect. HLD-0915 is designed to drive specific interactions between selected proteins to achieve optimal activity and pharmacology, as demonstrated in Halda’s preclinical studies. In preclinical prostate cancer models, orally delivered HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen (PSA), while delivering a favorable therapeutic index including in models of drug resistance. 

About Halda Therapeutics
Halda Therapeutics is a clinical-stage biotechnology company that has developed a proprietary RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) modality that works by a novel “hold and kill” mechanism for the precision treatment of cancer and other diseases. The novel mechanism of action of RIPTAC therapeutics is uniquely designed to address cancer’s ability to evolve bypass mechanisms of resistance, a common limitation of today’s precision oncology medicines. Our lead RIPTAC programs are in clinical and pre-clinical development for major solid tumor types with additional RIPTAC therapeutic programs in our pipeline to treat serious disease. Halda is led by a leadership team with deep expertise in biotechnology, drug discovery, platform innovation, and clinical development, and is located in New Haven, CT. For more information, please visit www.haldatx.com and follow us on LinkedIn.

Media Contact:
Kathryn Morris
The Yates Network LLC
914-204-6412
kathryn@theyatesnetwork.com